1. Home
  2. MPV vs NYXH Comparison

MPV vs NYXH Comparison

Compare MPV & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barings Participation Investors

MPV

Barings Participation Investors

HOLD

Current Price

$16.71

Market Cap

182.5M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$1.67

Market Cap

161.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPV
NYXH
Founded
1988
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Finance Companies
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.5M
161.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MPV
NYXH
Price
$16.71
$1.67
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
11.8K
501.1K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
8.71%
N/A
EPS Growth
N/A
N/A
EPS
1.71
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$213.98
Revenue Next Year
N/A
$126.25
P/E Ratio
$9.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.65
$1.26
52 Week High
$21.00
$8.59

Technical Indicators

Market Signals
Indicator
MPV
NYXH
Relative Strength Index (RSI) 44.32 35.28
Support Level $16.51 $1.26
Resistance Level $17.53 $1.70
Average True Range (ATR) 0.49 0.16
MACD -0.00 0.04
Stochastic Oscillator 49.06 88.89

Price Performance

Historical Comparison
MPV
NYXH

About MPV Barings Participation Investors

Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: